Therapeutic activation of caspases in cancer: A question of selectivity

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 2, 2003, Pages 179-187

  Beauparlant, Pierre ^a   Shore, Gordon C ^a  

^a INSTITUTE FOR RESEARCH IN IMMUNOLOGY AND CANCER   (Canada)

Author keywords

Apoptosis; Bcl 2; BH3; Caspase; Inhibitor of apoptosis proteins; Smac; Therapy; Tumor

Indexed keywords

ANTINEOPLASTIC AGENT; CASPASE; CELL PROTEIN; CYTOTOXIC AGENT; LIGAND; PROTEIN BCL 2; SECOND MITOCHONDRIAL ACTIVATOR OF CASPASE; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER; CANCER CELL; CANCER CHEMOTHERAPY; CARCINOGENESIS; CYTOTOXICITY; ENZYME ACTIVATION; ENZYME INHIBITION; REGULATORY MECHANISM; REVIEW; SENSOR; STRESS;

ANIMALS; APOPTOSIS; CASPASES; ENZYME ACTIVATION; GENES, BCL-2; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; INSECT PROTEINS; MITOCHONDRIA; NEOPLASMS; PROTEINS; SIGNAL TRANSDUCTION;

EID: 0037344678     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (84)

1. Shi Y: Mechanisms of caspase activation and inhibition during apoptosis. Mol Cell (2002) 9:459-740. This review presents the structure and function of caspases, and their regulation by IAP-mediated inhibition. Removal of caspase inhibition by Smac/DIABLO is also discussed.
2. Cory S, Adams JM: The Bcl2 family: Regulators of the cellular life-or-death switch. Nat Rev Cancer (2002) 2:647-656. A review of the intrinsic mitochondrial death pathway and the extrinsic death pathway regulation.
3. Letai A, Bassik MC, Walensky LD, Sorcinelli MD, Weiler S, Korsmeyer SJ: Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics. Cancer Cell (2002) 2:183-192. Two classes of BH3 domains exist: one that induces apoptosis by activating Bax and Bak, and the other that sensitizes cells to apoptosis by occupying the inhibitory BH3 binding pocket on Bcl-2 anti-apoptotic proteins.
4. Dijkers PF, Birkenkamp KU, Lam EWF, Thomas NSB, Lammers JWJ, Koenderman L, Coffer PJ: FKHR-L1 can act as a critical effector of cell death induced by cytokine withdrawal: Protein kinase B- enhanced cell survival through maintenance of mitochondrial integrity. J Cell Biol (2002) 156:531-542.
5. Mathai JP, Germain M, Marcellus RC, Shore GC: Induction and endoplasmic reticulum location of BIK/NBK in response to apoptotic signaling by E1A and p53. Oncogene (2002) 21:2534-2544.
6. Sax JK, Fei P, Murphy ME, Bernhard E, Korsmeyer SJ, El-Deiry WS: BID regulation by p53 contributes to chemosensitivity. Nat Cell Biol (2002) 4:842-849. Bid genomic loci contains p53-binding DNA response elements, and Bid expression in mouse colon and spleen cells is induced in a p53-dependent manner following γ-irradiation. Mouse embryo fibroblasts (MEF) lacking Bid are more resistant to adriamycin and 5-fluorouracil.
7. Kinoshita T, Yokota T, Arai K, Miyajima A: Regulation of Bcl-2 expression by oncogenic Ras protein in hematopoietic cells. Oncogene (1995) 10:2207-2212.
8. Liu H, Perlman H, Pagliari LJ, Pope RM: Constitutively activated Akt-1 is vital for the survival of human monocyte-differentiated macrophages: Role of Mcl-1, independent of nuclear factor (NF)-κB, Bad, or caspase activation. J Exp Med (2001) 194:113-126.
9. Kitamura S, Kondo S, Shinomura Y, Kanayama S, Miyazaki Y, Kiyohara T, Hiraoka S, Matsuzawa Y: Met/HGF receptor modulates Bcl-w expression and inhibits apoptosis in human colorectal cancers. Br J Cancer (2000) 83:668-673.
10. Ngan BY, Chen-Levy Z, Weiss LM, Warnke RA, Cleary ML: Expression in non-Hodgkin's lymphoma of the Bcl-2 protein associated with the t(14;18) chromosomal translocation. N Engl J Med (1988) 318:1638-1644. This paper presents the first indication that Bcl-2 proteins play a role in human cancers.
11. El-Deiry WS: Regulation of p53 downstream genes. Semin Cancer Biol (1998) 8:345-357.
12. Lassus P, Opitz-Araya X, Lazebnik Y: Requirement for caspase-2 in stress-induced apoptosis before mitochondrial permeabilization. Science (2002) 297:1352-1354. Caspase-2 is induced following stress-induced apoptosis. Caspase-2-silencing by small RNAi protects human fibroblasts transformed with the adenoviral oncogene E1A against apoptosis induced by etoposide, cisplatin and ultraviolet light.
13. Breckenridge DG, Nguyen M, Kuppig S, Reth M, Shore GC: The procaspase-8 isoform, procaspase-8L, recruited to the BAP31 complex at the endoplasmic reticulum. Proc Natl Acad Sci USA (2002) 99:4331-4336. Procaspase-8L is activated at the endoplasmic reticulum in response to the adenoviral oncogene E1A, independently of the death receptor pathway.
14. Chen G, Goeddel DV: TNF-R1 signaling: A beautiful pathway. Science (2002) 296:1634-1635. A review of TNF receptor signaling.
15. Krammer PH: CD95's deadly mission in the immune system. Nature (2000) 407:789-795. A review of Fas receptor signaling.
16. Srivastava RK: TRAIL/Apo-2L: Mechanisms and clinical applications in cancer. Neoplasia (2001) 3:535-546. A review of TRAIL receptor signaling.
17. Burns TF, Bernhard EJ, El-Deiry WS: Tissue specific expression of p53 target genes suggests a key role for KILLER/DR5 In p53- dependent apoptosis in vivo. Oncogene (2001) 20:4601-4612.
18. Zong WX, Lindsten T, Ross AJ, MacGregor GR, Thompson CB: BH3-only proteins that bind pro-survival Bcl-2 family members fail to induce apoptosis in the absence of Bax and Bak. Genes Dev (2001) 15:1481-1486. Apoptosis induction by Bim and Bad requires either Bax or Bak. MEF lacking Bax and Bak could be transformed as efficiently as MEF deficient in p53 by the combination of activated ras oncogene and myc.
19. Soengas MS, Alarcon RM, Yoshida H, Giaccia AJ, Hakem R, Mak TW, Lowe SW: Apaf-1 and caspase-9 in p53-dependent apoptosis and tumor inhibition. Science (1999) 284:156-159. MEF lacking Apaf-1 or caspase-9 could be transformed as efficiently as MEF deficient in p53 by the combination of activated ras oncogene and myc.
20. Degenhardt K, Sundararajan R, Lindsten T, Thompson C, White E: Bax and Bak independently promote cytochrome c release from mitochondria. J Biol Chem (2002) 277:14127-14134. Primary baby mouse kidney (BMK) epithelial cells deficient in Bax and Bak cannot be transformed by c-myc, but BMK epithelial cells deficient in p53 can.
21. Degenhardt K, Chen G, Lindsten T, White E: BAX and BAK mediate p53-independent suppression of tumorigenesis. Cancer Cell (2002) 2:193-203. In wild-type BMK epithelial cells, expression of E1A and inactivation of p53 are sufficient for cellular transformation, but not for tumorigenesis. Inactivation of Bax and Bak allow these cells to efficiently form tumors in nude mice.
22. Seoane J, Le HV, Massague J: Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature (2002) 419:729-734.
23. Dimanche-Boitrel MT, Garrido C, Chauffert B: Kinetic resistance to anticancer agents. Cytotechnology (1993) 12:347-356.
24. Evans DL, Tilby M, Dive C: Differential sensitivity to the induction of apoptosis by cisplatin in proliferating and quiescent immature rat thymocytes is independent of the levels of drug accumulation and DNA adduct formation. Cancer Res (1994) 54:1596-1603.
25. L is suppressed by Rb-mediated cell growth arrest.
26. Mandlekar S, Kong AN: Mechanisms of tamoxifen-induced apoptosis. Apoptosis (2001) 6:469-477.
27. Vasey PA, Jones NA, Jenkins S, Dive C, Brown R: Cisplatin, camptothecin, and taxol sensitivities of cells with p53-associated multidrug resistance. Mol Pharmacol (1996) 50:1536-1540.
28. Wilson WH, Teruya-Feldstein J, Fest T, Harris C, Steinberg SM, Jaffe ES, Raffeld M: Relationship of p53, Bcl-2, and tumor proliferation to clinical drug resistance in non-Hodgkin's lymphomas. Blood (1997) 89:601-609.
29. Hermine O, Haioun C, Lepage E, d'Agay MF, Briere J, Lavignac C, Fillet G, Salles G, Marolleau JP, Diebold J, Reyas F, Gaulard P: Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Étude des Lymphomes de l'Adulte (GELA). Blood (1996) 87:265-272.
30. L might be the crucial member of the Bcl-2 gene family in colorectal cancer. Dig Dis Sci (1998) 43:2641-2648.
31. Wilson JW, Nostro MC, Balzi M, Faraoni P, Cianchi F, Becciolini A, Potten CS: Bcl-w expression in colorectal adenocarcinoma. Br J Cancer (2000) 82:178-185.
32. L and Bcl-2 expression in squamous cell carcinoma of the head and neck. Cancer (1999) 85:164-170.
33. L expression lived significantly longer after tumor resection.
34. L. Am J Pathol (1996) 149:795-803.
35. Bauer JJ, Sesterhenn IA, Mostofi FK, McLeod DG, Srivastava S, Moul JW: Elevated levels of apoptosis regulator proteins p53 and Bcl-2 are independent prognostic biomarkers in surgically treated clinically localized prostate cancer. J Urol (1996) 156:1511-1516.
36. Cerroni L, Soyer HP, Kerl H: Bcl-2 protein expression in cutaneous malignant melanoma and benign melanocytic nevi. Am J Dermatopath (1995) 17:7-11.
37. Lazaridou A, Miraxtsi C, Korantzis J, Eleftheriadis N, Christakis JI: Simultaneous detection of Bcl-2 protein, trisomy 12, retinoblastoma and p53 monoallelic gene deletions in B-cell chronic lymphocytic leukemia by fluorescence in situ hybridization (FISH): Relation to disease status. Leuk Lymphoma (2000) 36:503-512.
38. Karakas T, Maurer U, Weidmann E, Miething CC, Hoelzer D, Bergmann L: High expression of Bcl-2 mRNA as a determinant of poor prognosis in acute myeloid leukemia. Ann Oncol(1998) 9:159-165.
39. Mikami T, Yanagisawa N, Baba H, Koike M, Okayasu I: Association of Bcl-2 protein expression with gallbladder carcinoma differentiation and progression and its relation to apoptosis. Cancer (1999) 85:318-325.
40. Eid H, Gulyas M, Geczi L, Bodrogi I, Institoris E, Bak M: Expression of Bcl-2 in testicular carcinoma: Correlation with tumor progression and MDR1/Pgp. Cancer (1998) 83:331-336.
41. Rodriguez-Pereira C, Suarez-Penaranda JM, Barros F, Sobrido MJ, Vazquez-Salvado M, Forteza J: Analysis of 2 antiapoptotic factors in gliomas: Bcl-2 overexpression and p53 mutations. Arch Pathol Lab Med (2001) 125:218-223.
42. Elledge RM, Green S, Howes L, Clark GM, Berardo M, Allred DC, Pugh R, Ciocca D, Ravdin P, O'Sullivan J, Rivkin S, Martino S, Osborne CK: Bcl-2, p53, and response to tamoxifen in estrogen receptor-positive metastatic breast cancer: A Southwest Oncology Group study. J Clin Oncol (1997) 15:1916-1922. cContrary to expectation, high Bcl-2 expression correlates with estrogen receptor-positive metastatic breast cancer, with better clinical response to tamoxifen and a longer patient survival.
43. L or Bax) mRNA and protein expression. p53 Protein levels were not affected by tamoxifen.
44. Beale PJ, Rogers P, Boxall F, Sharp SY, Kelland LR: Bcl-2 family protein expression and platinum drug resistance in ovarian carcinoma. Br J Cancer (2000) 82:436-440.
45. L is a chemoresistance factor in human melanoma cells that can be inhibited by antisense therapy. Int J Cancer (2002) 99:29-34.
46. L in a human ovarian carcinoma cell line: Paradoxic effects on chemosensitivity in vitro versus in vivo. Int J Cancer (2002) 97:858-863.
47. Lopes de Menezes DE, Hudon N, McIntosh N, Mayer LD: Molecular and pharmacokinetic properties associated with the therapeutics of Bcl-2 antisense oligonucleotide G3139 combined with free and liposomal doxorubicin. Clin Cancer Res (2000) 6:2891-2902.
48. Gleave M, Tolcher A, Miyake H, Nelson C, Brown B, Beraldi E, Goldie J: Progression to androgen independence is delayed by adjuvant treatment with antisense Bcl-2 oligodeoxynucleotides after castration in the LNCaP prostate tumor model. Clin Cancer Res (1999) 5:2891-2898.
49. Klasa RJ, Bally MB, Ng R, Goldie JH, Gascoyne RD, Wong FM: Eradication of human non-Hodgkin's lymphoma in SCID mice by Bcl-2 antisense oligonucleotides combined with low-dose cyclophosphamide. Clin Cancer Res (2000) 6:2492-2500.
50. Jansen B, Schlagbauer-Wadl H, Brown BD, Bryan RN, van Elsas A, Muller M, Wolff K, Eichler HG, Pehamberger H: Bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice. Nat Med (1998) 4:232-234.
51. Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, Pehamberger H, Jansen B: Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol (2000) 114:725-730.
52. Zangemeister-Wittke U, Schenker T, Luedke GH, Stahel RA: Synergistic cytotoxicity of Bcl-2 antisense oligodeoxynucleotides and etoposide, doxorubicin and cisplatin on small-cell lung cancer cell lines. Br J Cancer (1998) 78:1035-1042.
53. L-bispecific antisense oligonucleotide against tumors of diverse histologic origins. J Natl Cancer Inst (2001) 93:463-471.
54. L bispecific antisense oligonucleotide.
55. Chi KC, Wallis AE, Lee CH, De Menezes DL, Sartor J, Dragowska WH, Mayer LD: Effects of Bcl-2 modulation with G3139 antisense oligonucleotide on human breast cancer cells are independent of inherent Bcl-2 protein expression. Breast Cancer Res Treat (2000) 63:199-212. G-3139 was tested in MCF-7 and MDA435/LCC6 human breast cancer cells, and similar cytotoxic effects were observed in both cell lines despite a 9-fold intrinsic difference in Bcl-2 protein expression.
56. Cotter FE, Johnson P, Hall P, Pocock C, al Mahdi N, Cowell JK, Morgan G: Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model. Oncogene (1994) 9:3049-3055.
57. Kumazaki T, Sasaki M, Nishiyama M, Teranishi Y, Sumida H, Mitsui Y: Effect of Bcl-2 down-regulation on cellular life span. Biogerontology (2002) 3:291-300.
58. Ackermann EJ, Taylor JK, Narayana R, Bennett CF: The role of antiapoptotic Bcl-2 family members in endothelial apoptosis elucidated with antisense oligonucleotides. J Biol Chem (1999) 274:11245-11252.
59. L expression sensitizes normal human keratinocytes and epithelial cells to apoptotic stimuli. Oncogene (1999) 18:4495-4504.
60. L antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages. J Invest Dermatol (2002) 118:505-512.
61. Waters JS, Webb A, Cunningham D, Clarke PA, Raynaud F, di Stefano F, Cotter FE: Phase I clinical and pharmacokinetic study of Bcl-2 antisense oligonucleotide therapy in patients with non-Hodgkin's lymphoma. J Clin Oncol (2000) 18:1812-1823.
62. Agrawal S, Kandimalla ER: Antisense and/or immunostimulatory oligonucleotide therapeutics. Curr Cancer Drug Targets (2001) 1:197-209.
63. Jahrsdorfer B, Jox R, Muhlenhoff L, Tschoep K, Krug A, Rothenfusser S, Meinhardt G, Emmerich B, Endres S, Hartmann G: Modulation of malignant B cell activation and apoptosis by Bcl-2 antisense ODN and immunostimulatory CpG ODN. J Leukocyte Biol (2002) 72:83-92.
64. Finnegan NM, Curtin JF, Prevost G, Morgan B, Cotter TG: Induction of apoptosis in prostate carcinoma cells by BH3 peptides which inhibit Bak/Bcl-2 interactions. Br J Cancer (2001) 85:115-121. PC3 and DU145 prostate cancer cells undergo apoptosis when electroporated with Bax or Bak BH3 peptides. Electroporation of Bik BH3 peptide has no effect on cell viability.
65. Wang JL, Zhang ZJ, Choksi S, Shan S, Lu Z, Croce CM, Alnemri ES, Korngold R, Huang Z: Cell permeable Bcl-2 binding peptides: A chemical approach to apoptosis induction in tumor cells. Cancer Res (2000) 60:1498-1502. One of the few demonstrations that Bad BH3 peptide selectively induces apoptosis in cancer cells. Bad BH3 peptide, made cell-permeable by attaching a fatty acid, showed selective killing of HL60 cells versus mitogen-stimulated peripheral blood leukocytes, and improved survival of SCID mice challenged with HL60 cells intraperitoneally.
66. Radetzki S, Kohne CH, von Haefen C, Gillissen B, Sturm I, Dorken B, Daniel PT: The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines. Oncogene (2002) 21:227-238.
67. L.
68. L. Nat Cell Biol (2001) 3:173-182.
69. Lugovskoy AA, Deqterev Al, Fahmy AF, Zhou P, Gross JD, Yuan J, Wagner G: A novel approach for characterizing protein ligand complexes: Molecular basis for specificity of small-molecule Bcl-2 inhibitors. J Am Chem Soc (2002) 124:1234-1240.
70. Wang JL, Liu D, Zhang ZJ, Shan S, Han X, Srinivasula SM, Croce CM, Alnemri ES, Huang Z: Structure-based discovery of an organic compound that binds Bcl-2 protein and induces apoptosis of tumor cells. Proc Natl Acad Sci USA (2000) 97:7124-7129. The first in vitro small molecule inhibitor of the Bcl-2 family of anti-apoptotic proteins to be published.
71. Enyedy IJ, Ling Y, Nacro K, Tomita Y, Wu X, Cao Y, Guo R, Li B, Zhu X, Huang Y, Long YQ, Roller PP, Yang D, Wang S: Discovery of small-molecule inhibitors of Bcl-2 through structure-based computer screening. J Med Chem (2001) 44:4313-4324.
72. Tzung SP, Kim KM, Basanez G, Giedt CD, Simon J, Zimmerberg J, Zhang KY, Hockenbery DM: Antimycin A mimics a cell-death- inducing Bcl-2 homology domain 3. Nat Cell Biol (2001) 3:183-191.
73. Kim KM, Giedt CD, Basanez G, O'Neill JW, Hill JJ, Han YH, Tzung SP, Zimmerberg J, Hockenbery DM, Zhang KY: Biophysical characterization of recombinant human Bcl-2 and its interactions with an Inhibitory ligand, antimycin A. Biochemistry (2001) 40:4911-4922.
74. L may function as an ion channel in the outer membrane to prevent osmotic swelling of mitochondria.
75. Kutzki O, Park HS, Ernst JT, Orner BP, Yin H, Hamilton AD. Development of a potent Bcl-XL antagonist based on α-helix mimicry. J Am Chem Soc (2002) 124:11838-11839.
76. Sasaki H, Sheng Y, Kotsuji F, Tsang BK: Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Cancer Res (2000) 60:5659-5666.
77. Arnt CR, Chiorean MV, Heldebrant MP, Gores GJ, Kaufmann SH: Synthetic Smac/DIABLO peptides enhance the effects of chemotherapeutic agents by binding XIAP and clAP1 in situ. J Biol Chem (2002) 277:44236-44243.
78. Fulda S, Wick W, Weller M, Debatin KM: Smac agonists sensitize for Apo2L/TRAIL- or anticancer drug-induced apoptosis and induce regression of malignant glioma in vivo. Nat Med (2002) 8:808-815. The first demonstration that synthetic Smac agonists can sensitize tumors to TRAIL or cytotoxic agents.
79. de Jong S, Timmer T, Heijenbrok FJ, de Vries EG: Death receptor ligands, in particular TRAIL, to overcome drug resistance. Cancer Metastasis Rev (2001) 20:51-56.
80. Nitsch R, Bechmann I, Deisz RA, Haas D, Lehmann TN, Wendling U, Zipp F: Human brain-cell death induced by tumour-necrosis-factor-related apoptosis-inducing ligand (TRAIL). Lancet (2000) 356:827-828.
81. Jo M, Kim TH, Seol DW, Esplen JE, Dorko K, Billiar TR, Strom SC: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat Med (2000) 6:564-567.
82. Deng Y, Lin Y, Wu X: TRAIL-induced apoptosis requires Bax- dependent mitochondrial release of Smac/DIABLO. Genes Dev (2002) 16:33-45.
83. Shivapurkar N, Toyooka S, Eby MT, Huang CX, Sathyanarayana UG, Cunningham HT, Reddy JL, Brambilla E, Takahashi T, Minna JD, Chaudhary PM, Gazdar AF: Differential inactivation of caspase-8 in lung cancers. Cancer Biol Ther (2002) 1:65-69.
84. Tang X, Sun YJ, Half E, Kuo MT, Sinicrope F: Cyclooxygenase-2 overexpression inhibits death receptor 5 expression and confers resistance to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human colon cancer cells. Cancer Res (2002) 62:4903-4908. HCT15 colon cancer cells lack COX-2 expression. Ectopic expression of COX-2 inhibits DR5 expression in HCT15 cells. Sulindac (exisulind; Cell Pathways Inc) restores DR5 expression and sensitivity to TRAIL.